[go: up one dir, main page]

HK1117524B - Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine - Google Patents

Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine Download PDF

Info

Publication number
HK1117524B
HK1117524B HK08108277.9A HK08108277A HK1117524B HK 1117524 B HK1117524 B HK 1117524B HK 08108277 A HK08108277 A HK 08108277A HK 1117524 B HK1117524 B HK 1117524B
Authority
HK
Hong Kong
Prior art keywords
lower alkyl
phenyl
compound
formula
methyl
Prior art date
Application number
HK08108277.9A
Other languages
German (de)
French (fr)
Chinese (zh)
Other versions
HK1117524A1 (en
Inventor
Joseph Mckenna
Wen-Chung Shieh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/US2006/022155 external-priority patent/WO2006135641A2/en
Publication of HK1117524A1 publication Critical patent/HK1117524A1/en
Publication of HK1117524B publication Critical patent/HK1117524B/en

Links

Description

Background of the Invention
The present invention provides a new method of making compounds of formula (I): wherein
  • R1 is mono- or polysubstituted aryl;
  • R2 is hydrogen, lower alkyl or aryl; and
  • R4 is hydrogen, lower alkyl, or halogen.
Compounds of formula (I) have been disclosed in W. Breitenstein et al., WO 04/005281 which published on January 15, 2004 , the disclosure of which is incorporated by reference. A preferred compound of formula (I) is 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5: (4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide (Ia). Compounds of formula (I) have been shown to inhibit one or more tyrosine kinases, such as c-Abl, Bcr-Abl, the receptor tyrosine kinases PDGF-R, FIt3, VEGF-R, EGF-R and c-Kit. As such, compounds of formula (I) can be used for the treatment of certain neoplastic diseases, such as leukemia.
Previous synthesis of compounds of formula (I), and specifically (Ia), involves a hydrolysis of an ethyl ester to a carboxylic acid, which is then reacted with an aniline, and employing diethylcyanophosphonate as a coupling agent as shown in Scheme 1.
This process gives low and inconsistent yields. Furthermore, diethylcyanophosphonate is an expensive reagent. Thus, there is a need for an alternate process that is cheaper, consistent, efficient, and produces compounds (I) in high yields.
It is an object of this invention to provide for an alternative process to make compounds of formula (I) efficiently with high and consistent yields.
It is a further object of this invention to make compounds of formula (I) from lower cost reagents.
It is a still further object of this invention to provide for a process to make compounds of formula (I) utilizing safer reagents.
The present invention overcomes the problems encountered in the previous synthesis described in Scheme 1 and typically resulted in an increased overall yield from 54-86%.
Summary of the Invention
The present invention provides a new method of making compounds of formula (I): comprising the following reaction: wherein
  • R1 is substituted or unsubstituted aryl;
  • R2 is hydrogen, lower alky or aryl;
  • R4 is hydrogen, lower alkyl or halogen; and
  • R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl.
Direct condensation of ester (II) with aniline (IV) is catalyzed by a base, such as potassium tert-butoxide to make compounds of formula (I). The process is carried out at temperature between -50°C to 50°C in an organic solvent of tetrahydrofuran, dimethylformamide, toluene or N-methylpyrrolidinone.
Detailed Description of the Invention
The general reaction scheme of the invention can be illustrated as follows: wherein
  • R1 is substituted or unsubstituted aryl;
  • R2 is hydrogen, lower alky or aryl;
  • R4 is hydrogen, lower alkyl or halogen; and
  • R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl.
Direct condensation of ester (II) with aniline (IV) can be catalyzed by a strong base such as potassium tert-butoxide to make compounds of formula (I) in good yield and high purity without any chromatography or recrystallization purification. Other bases, such as metal hydride, bulkyl alkyl lithium, metal alkoxide, metal bis(trimethylsilyl) amide or lithium dialkylamide, can also be used. The metal can be lithium, sodium or potassium. The process is carried out at temperature between -50°C to 50°C in an organic solvent of tetrahydrofuran, dimethylformamide, toluene or N-methylpyrrolidinone.
In a preferred embodiment, the process comprises the following reaction: wherein R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl.
The compound of formula (IVa) can be prepared using processes disclosed in patent applications U.S. SN 60/688,920 and SN 60/688,976 , both entitled "Process for the Synthesis of Organic Compounds", which were filed concurrently herewith. The disclosures of those applications are incorporated herein by reference.
In the most preferred embodiment, the process comprises the following reaction:
As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below.
Lower alkyl comprises 1-6 carbon atoms, and is linear or branched; preferred lower alkyl moieties are butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl. Particularly preferred lower alkyl moieties are methyl, ethyl, n-propyl or tert-butyl.
An aryl group is an aromatic radical which is bound to the molecule via a bond located at an aromatic ring carbon atom of the radical. In a preferred embodiment, aryl is an aromatic radical having 6-14 carbon atoms, especially phenyl, naphthyl, tetrahydronaphthyl, fluorenyl or phenanthrenyl, and is unsubstituted or substituted by one or more, preferably up to three, especially one or two substituents, wherein the substituents are heterocyclyl groups comprising one, two, three ring nitrogen atoms, one oxygen atom or one sulfur atom; other substituents on aryl include disubstituted amino, halogen, lower alkyl, substituted lower alkyl, lower alkenyl, lower alkynyl, phenyl, etherified hydroxy, esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, benzoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, ureido, mercapto, sulfo, lower alkylthio, phenylthio, phenyl-lower alkylthio, lower alkylphenylthio, lower alkylsulfinyl, phenylsulfinyl, phenyl-lower alkylsulfinyl, lower alkylphenylsulfinyl, lower alkylsulfonyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, lower alkylphenylsulfonyl, halogen-lower alkylmercapto, halogen-lower alkylsulfonyl, such as especially trifluoromethanesulfonyl, heterocyclyl, a mono- or bicyclic heteroaryl group or lower alkylene dioxy bound at adjacent C-atoms of the ring, such as methylene dioxy. According to a preferred embodiment, aryl is phenyl, naphthyl or tetrahydronaphthyl, which in each case is either unsubstituted or independently substituted by one or two substituents selected from the group consisting of halogen, especially fluorine, chlorine or bromine; hydroxy etherified by lower alkyl, e.g., by methyl, by halogen-lower alkyl, e.g., trifluoromethyl, or by phenyl; lower alkylene dioxy bound to two adjacent C-atoms, e.g., methylenedioxy, lower alkyl, e.g., methyl or propyl; halogen-lower alkyl, e.g., trifluoromethyl; hydroxy-lower alkyl, e.g., hydroxymethyl or 2-hydroxy-2-propyl; lower alkoxy-lower alkyl; e.g., methoxymethyl or 2-methoxyethyl; lower alkoxycarbonyl-lower alkyl, e.g., methoxycarbonylmethyl; lower alkynyl, such as 1-propynyl; esterified carboxy, especially lower alkoxycarbonyl, e.g., methoxycarbonyl, n-propoxy carbonyl or isopropoxy carbonyl; N-monosubstituted carbamoyl, in particular, carbamoyl monosubstituted by lower alkyl, e.g., methyl, n-propyl or isopropyl; di-lower alkylamino, e.g., dimethylamino or diethylamino; lower alkylene-amino, e.g., pyrrolidino or piperidino; lower oxaalkylene-amino, e.g., morpholino, lower azaalkylene-amino, e.g., piperazino, acylamino, e.g., acetylamino or benzoylamino; lower alkylsulfonyl, e.g., methylsulfonyl; sulfamoyl; and phenylsulfonyl.
Halogen is fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine.
The following examples more particularly illustrate the present invention, but do not limit the invention in any way.
Example 1 Synthesis of compound of formula (Ia)
To a 1-L flask, equipped with a mechanical stirrer, temperature sensor, reflux condenser, addition funnel and nitrogen inlet-outlet under a nitrogen atmosphere at 23°C is charged with compounds (IIc) (16 g), (IVa) (12 g) and THF (300 mL). The mixture is stirred for 15 minutes at 23°C and cooled to -20°C to -15°C. A solution of 1 M potassium t-butoxide in THF (275 mL) is added at -20°C to -10°C. After the addition, the mixture is warmed to 18-23°C. When the reaction is complete according to HPLC, the mixture is cooled to 5°C. A solution of 15% aqueous sodium chloride (500 mL) is added to the mixture, maintaining temperature below 15°C. Product is extracted into isopropyl acetate (500 mL) and washed in sequence with 15% aqueous sodium chloride solution (500 mL) and water (500 mL). The organic phase is distilled under atmospheric pressure at an internal temperature of 75-85°C until the residual volume is about 200 mL. The resulting suspension is cooled to 70 ± 5°C and charged with ethanol (250 mL) and water (30 mL). The mixture is heated to reflux (78°C) for 1 hour and then cooled to -10°C to -15°C. The suspension is stirred for an additional 30 minutes at -10°C to -15°C. Any solid is collected by filtration, rinsed with cold (5°C) ethanol (85 mL) and dried under vacuum (10-20 torr) 1.3-2.7 kPa at 55-60°C with a nitrogen bleed (8-16 hours) to obtain AMN107 (17.4 g, 67% yield) as a white solid. 1H NMR 300 MHz, DMSO-d6), δ 10.5 (s, 1H), 9.15 (s, 1H), 9.05 (s, 1H), 8.60 (s, 1H), 8.45 (d, 1H), 8.35 (d, 1H), 8.22 (d, 2H), 8.10 (d, 2H), 7.65 (m, 2H), 7.45 (m, 4H), 2.25 (s, 3H), 2.05 (s, 3H).

Claims (7)

  1. A process for the preparation of compounds of formula (I) comprising reacting the compound: with R1-NH-R2, wherein
    R1 is substituted or unsubstituted aryl;
    R2 is hydrogen, lower alky or aryl;
    R4 is hydrogen, lower alkyl or halogen; and
    R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl, and wherein the process is catalyzed by a base in an organic solvent.
  2. A process for the preparation of a compound of the formula (Ia) comprising reacting the compound: wherein R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl, with the compound 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine of the structure (IVa): and wherein the process is catalyzed by a base in an organic solvent.
  3. A process for the preparation of a compound of the formula (Ia) comprising reacting the compound: with 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine (IVa) wherein the process is catalyzed by a base in an organic solvent.
  4. The process of any one of Claims 1-3, wherein the base is selected from the group consisting of metal hydride, bulky alkyl lithium, metal alkoxide, metal bis(trimethylsilyl)amide and lithium dialkylamide.
  5. The process of Claim 4, wherein the metal is selected from the group consisting of lithium, sodium and potassium.
  6. The process of Claim 4, wherein the base is potassium tert-butoxide.
  7. The process of any one of Claims 1-3, wherein the organic solvent is selected from the group of tetrahydrofuran, dimethylformamide, toluene and N-methylpyrrolidone.
HK08108277.9A 2005-06-09 2006-06-07 Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine HK1117524B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US60/688,977 2005-06-09
US70559005P 2005-08-04 2005-08-04
US60/705,590 2005-08-04
PCT/US2006/022155 WO2006135641A2 (en) 2005-06-09 2006-06-07 PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE

Publications (2)

Publication Number Publication Date
HK1117524A1 HK1117524A1 (en) 2009-01-16
HK1117524B true HK1117524B (en) 2010-12-31

Family

ID=

Similar Documents

Publication Publication Date Title
US8946416B2 (en) Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
US5162326A (en) Pyrimidinedione derivatives, their production and use
Atwal et al. Substituted 1, 4-dihydropyrimidines. 3. Synthesis of selectively functionalized 2-hetero-1, 4-dihydropyrimidines
CA2020370A1 (en) Pyrimidine derivatives
EP0234830A1 (en) 2-(Substituted imino)-6-aryl-3,6-dihydro-4-substituted-1,5(2H)-pyrimidinecarboxylic acids and analogs
HU229937B1 (en) Condensed azepines as vasopressin agonists, the use of the compounds or their pharmaceutical salts as a component of pharmaceutical composition or for the preparation the same and pharmaceutical composition containing them
JP4268871B2 (en) Method for producing pyrimidinone compounds and pharmaceutically acceptable salts thereof
EA010392B1 (en) Imidazole derivatives, the production thereof, and the use of the same as a medicament
HK1117524B (en) Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
CN101184748B (en) Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
JPH06211814A (en) (Thio) urea derivative
CN110028502B (en) Preparation method of kinase inhibitor drug intermediate
CN112341344B (en) Preparation method of kinase inhibitor intermediate
JPH04330072A (en) Pyrimidinedione derivative
CN120004811A (en) Novel method for synthesizing 2-hydrazino-substituted pyrimidine
KR100539725B1 (en) New alkylation of pyrrole compound
JP2005126389A (en) Process for producing 2,4-dichloro-5-fluoropyrimidine
JPH09208581A (en) Pyrrolylbenzimidazole derivative